Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Epidermolysis Bullosa Clinical Trials

A listing of Epidermolysis Bullosa medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (4) clinical trials

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

The proposed 40 week pilot study being conducted is a prospective, double-blind, randomized, placebo-controlled crossover study. Participants will be assigned to treat both feet with either topical sirolimus, 2% cream daily or placebo (vehicle-control) for 12 weeks, followed by a 4 week washout period, then re-treatment to both feet will ...


Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects With Epidermolysis Bullosa Simplex (EBS)

The proposed study is an international, multicenter, randomized, double-blind, vehicle-controlled, parallel group study to evaluate the safety and efficacy of topical Diacerein 1% Ointment for the treatment of subjects with EBS. Subject randomization will be stratified by genotype (KRT5 and/or KRT14 versus other genotypes) and age group (<8 and 8 ...


Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

The primary objective of this study is to estimate the event-free survival rate by 1 year post-transplant with an event defined as a death or failure to have a demonstrable increase in collagen, laminin, integrin, keratin or plakin deposition by 1 year post-transplant or other biochemical, structural or physical measure ...


MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the biochemical correction of severe epidermolysis bullosa (EB).